Connecticut is currently home to 1247 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
NCT05077904
Recruiting
The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/31/2025
Locations: Ep0162 50367, New Haven, Connecticut
Conditions: Stereotypical Prolonged Seizures
Register for Updates
In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans
NCT04920539
Recruiting
In this study, the investigators hypothesize that THC alters the immunogenome in a cell type-specific fashion and alters cytokine production via epigenetic regulatory mechanisms and that these alterations differ between HIV-infected and HIV-uninfected host genomes.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/31/2025
Locations: VA Connecticut Healthcare System, West Haven, Connecticut
Conditions: HIV Infections, Healthy
Register for Updates
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
NCT04743765
Recruiting
The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assess... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/31/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Hip Fractures, Myocardial Injury
Register for Updates
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
NCT04530565
Recruiting
This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the same treatment plus blinatumomab. Blinatumomab is a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/31/2025
Locations: Yale University, New Haven, Connecticut
Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
NCT04267848
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437
Recruiting
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During thi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/31/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Register for Updates
SV2 PET Imaging With [11C]APP311
NCT03995121
Recruiting
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/31/2025
Locations: Conneticut Mental Health Center, New Haven, Connecticut
Conditions: Schizophrenia and Other Psychotic Disorders, Cannabis Use Disorder, Healthy
Register for Updates
Pan Tumor Rollover Study
NCT03899155
Recruiting
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Local Institution - 0095, New Haven, Connecticut
Conditions: Cancer
Register for Updates
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Yale Cancer Center ( Site 0014), New Haven, Connecticut
Conditions: Solid Tumors, Hematologic Malignancies
Register for Updates
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
NCT06882746
Recruiting
This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the highest dose for the study medicine called BI 765049 that people with advanced cancer can tolerate. Another purpose is to find the most suitable dose and best way of administration of BI 765049 for furt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
Register for Updates
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
NCT06846320
Recruiting
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2025
Locations: Connecticut Clinical Research - Cromwell /ID# 271241, Cromwell, Connecticut
Conditions: Generalized Anxiety Disorder (GAD)
Register for Updates
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153
Recruiting
The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's disease occurring in participants receiving study drug compared to placebo. Participation could last up to 255 weeks including screening, a double-blind treatment period, and a double-blind observation period. In addition, eligible participants who receive placebo during the double-blind treatment period may choose to extend their study participat... Read More
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
07/30/2025
Locations: Invicro, New Haven, Connecticut
Conditions: Alzheimer's Disease
Register for Updates